Fiche centre
UC Davis Medical Center
Sacramento — United States
Essais liés9clinical trials
VilleSacramentolocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07227246
Essais cliniques associés
9| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Recombinant Factor VIIa | Accident vasculaire cérébral | Phase 3 | NCT07227246 | FASTEST Part 2 — Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2 | RECRUITING |
| Photodynamic therapy-Photofrin | Cancer | Phase 3 | NCT02082522 | Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS) | TERMINATED |
| AOC 1044 | Myopathies | Phase 2 | NCT06244082 | EXPLORE44OLE — Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping | ACTIVE_NOT_RECRUITING |
| Sevasemten 10 mg | Myopathies | Phase 2 | NCT05291091 | Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) | COMPLETED |
| Sevasemten | Myopathies | Phase 2 | NCT06066580 | MESA — Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy | ENROLLING_BY_INVITATION |
| temporally-interfering electric field stimulation | Épilepsie | Non applicable | NCT06716866 | EE-DES-TIEF — Temporally Interfering Electric Field Stimulation in the Treatment of Epilepsy | ENROLLING_BY_INVITATION |
| Sevasemten Dose 1 | Myopathies | Phase 2 | NCT06100887 | FOX — Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy | ACTIVE_NOT_RECRUITING |
| (-)-Epicatechin | Myopathies | Phase 2 | NCT03236662 | (-)- Epicatechin Becker Muscular Dystrophy | COMPLETED |
| Paradise Ultrasound Renal Denervation Treatment | Hypertension | À vérifier | NCT06297291 | US GPS — Global Paradise System US Post Approval Study | RECRUITING |